LOGIN  |  REGISTER
C4 Therapeutics

Ginkgo Bioworks to Participate in Two Conferences in May

May 15, 2024 | Last Trade: US$10.08 1.34 15.33

BOSTON, May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May.

  • TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET on May 22, 2024.
  • Leerink Partners Healthcare Crossroads Conference: Ginkgo's Chief Business Officer, Ena Cratsenburg, will host a fireside chat at 10:40 am CT (11:40 am ET) on May 30, 2024.

Further details, webcast links, and a replay of the presentations, fireside chats, and panels, if available, will be posted on the company's investor relations website at investors.ginkgobioworks.com.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB